Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 26, 2021

View Archived Issues

CT-859 improves survival in a murine NASH model

New animal model reveals effects of TM6SF2 gene variant on VLDL lipidation

Preclinical data presented for recombinant myxoma virus MC509-N1 in cancer

Adenosine A2A receptor antagonists identified at Adorx Therapeutics

New MAP4K1 inhibitors synthesized at Pfizer

Takeda Pharmaceutical presents new ABCC2 inhibitors

Merck, Cancer Research Technology divulge YAP1/TEAD interaction inhibitors

Sinocelltech patents Fc fragment fusion protein glycoconjugates

Study reports tumors change as patients age

Glycotope's tumor-targeting IL-15-based immunocytokine shows efficacy in preclinical models

Repurposing of riluzole for the treatment of Niemann-Pick disease, type C1

Attenuated measles vaccine expressing the S antigen protects mice and hamsters from SARS-CoV-2

SHP-1 abundance determines the responsiveness of an individual NK cell

Compounds targeting NPC1 protein show promising antiviral activity against SARS-CoV-2

Osteoclasts modified with tetracycline show efficacy in models of heterotopic ossification

ALD-2510 selectively depletes tumor-infiltrating Tregs for activity in vivo

Polycystic ovary syndrome murine model reveals CYP17 involvement

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
New 5-HT2C receptor agonists reported in Hansoh patent
BioWorld Science
Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...